Effect of enteric coating on antiplatelet activity of low-dose as.pdf (243.81 kB)
0/0

Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers.

Download (243.81 kB)
journal contribution
posted on 22.11.2019 by Dermot Cox, Andrew O. Maree, Michelle Dooley, Ronán Conroy, Michael F. Byrne, Desmond J. Fitzgerald

BACKGROUND AND PURPOSE: Aspirin resistance may be relatively common and associated with adverse outcome. Meta-analysis has clearly shown that 75 mg plain aspirin is the lowest effective dose; however, it is not known whether the recent increased use of enteric-coated aspirin could account for aspirin resistance. This study was designed to determine whether enteric-coated aspirin is as effective as plain aspirin in healthy volunteers. METHODS: Seventy-one healthy volunteers were enrolled in 3 separate bioequivalence studies. Using a crossover design, each volunteer took 2 different aspirin preparations. Five aspirin preparations were evaluated, 3 different enteric-coated 75-mg aspirins, dispersible aspirin 75 mg and asasantin (25-mg standard release aspirin plus 200-mg modified-release dipyridamole given twice daily). Serum thromboxane (TX) B2 levels and arachidonic acid-induced platelet aggregation were measured before and after 14 days of treatment. RESULTS: All other aspirin preparations tested were inferior to dispersible aspirin (P99%) inhibition (P

History

Comments

This article is available at http://stroke.ahajournals.org

Published Citation

Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006;37(8):2153-8

Publication Date

01/08/2006

Publisher

Lippincott Williams & Wilkins

PubMed ID

16794200

Exports